SPDR S&P Biotech ETF
432 hedge funds and large institutions have $5.71B invested in SPDR S&P Biotech ETF in 2018 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 174 increasing their positions, 119 reducing their positions, and 50 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
4.69% less ownership
Funds ownership: 111.25% → 106.56% (-4.7%)
9% less funds holding in top 10
Funds holding in top 10: 22 → 20 (-2)
59% less call options, than puts
Call options by funds: $762M | Put options by funds: $1.86B
Holders
432
Holding in Top 10
20
Calls
$762M
Puts
$1.86B
Top Buyers
| 1 | +$185M | |
| 2 | +$156M | |
| 3 | +$48.1M | |
| 4 |
Goldman Sachs
New York
|
+$43.6M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$39.9M |
Top Sellers
| 1 | -$221M | |
| 2 | -$127M | |
| 3 | -$110M | |
| 4 |
State of Tennessee, Department of Treasury
Nashville,
Tennessee
|
-$43.6M |
| 5 |
AssetMark Inc
Concord,
California
|
-$41.5M |